Latest From GC Pharma
Chinese venture funding to the US biotech sector has fallen by nearly 60% in the latest sign of cooling in the previously booming bilateral life sciences investment sector.
Leading South Korean pharma firm GC Pharma realigns R&D priorities and resources and changes US strategy amid delayed approval of its immunoglobulin product.
Q1 2019 saw a jump in merger and acquisition activity. Informa’s Biomedtracker has cast an analytical eye on three of the major deals, namely buys by Roche, Lilly and BMS.
Although the big decision has been made for Invossa in Korea, things have not settled down and there have been calls for re-examination of all approved cell therapies, the recall of R&D grants provided to Kolon and expansion of a probe into the company’s leadership and government officials.
- OTC, Consumer
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Infectious & Viral Diseases
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Green Cross Corp.
- South Korea
- Pacific Rim
- Parent & Subsidiaries
- GC Pharma
- Senior Management
- Soon-Tae Cho, Pres.
- Contact Info
Phone: (82) 31 260 9300
107, Ihyeon-ro 30 beon-gil, Giheung-gu
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.